Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ).
Zylox-Tonbridge Medical Technology Co., Ltd. has announced a significant increase in its financial performance for the first half of 2025, with revenue expected to exceed RMB480 million, a 31.1% increase from the previous year. This growth is attributed to strong sales of key products and an effective sales strategy. Net profit is also anticipated to rise by 66.9% to over RMB115 million, driven by increased revenue, stable gross profit margins, and enhanced operational efficiency.
The most recent analyst rating on (HK:2190) stock is a Buy with a HK$18.60 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a company incorporated in China, specializing in medical technology. Its primary products include the Kylin Flow Diverter, Neurovascular Guidewire, UltraFree Drug Coated PTA Balloon Catheter, Octoplus Vena Cava Filter, and Phoenix Peripheral Detachable Fibrous Coil Embolization System, focusing on the medical device industry.
Average Trading Volume: 616,819
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.15B
See more data about 2190 stock on TipRanks’ Stock Analysis page.